|
CN104520324A
(zh)
|
2012-02-24 |
2015-04-15 |
施特姆森特Rx股份有限公司 |
Dll3调节剂及其使用方法
|
|
PL3489261T3
(pl)
|
2012-08-24 |
2021-08-16 |
The Regents Of The University Of California |
Przeciwciała i szczepionki do stosowania w leczeniu nowotworów z ekspresją ROR1 i w hamowaniu przerzutu
|
|
ES2731681T3
(es)
|
2013-02-22 |
2019-11-18 |
Abbvie Stemcentrx Llc |
Conjugados de anticuerpo anti-DLL3 y PBD y usos de los mismos
|
|
JP2016531915A
(ja)
|
2013-08-28 |
2016-10-13 |
ステムセントリックス， インコーポレイテッド |
部位特異的抗体コンジュゲーション方法および組成物
|
|
CA2922529A1
(en)
|
2013-08-28 |
2015-03-05 |
Stemcentrx, Inc. |
Novel sez6 modulators and methods of use
|
|
EP3107576A4
(en)
|
2014-02-21 |
2017-09-06 |
Abbvie Stemcentrx LLC |
Anti-dll3 antibodies and drug conjugates for use in melanoma
|
|
MA41645A
(fr)
*
|
2015-03-04 |
2018-01-09 |
Abbvie Stemcentrx Llc |
Anticorps issus de génie génétique spécifiques au site et méthodes d'utilisation
|
|
GB201506411D0
(en)
|
2015-04-15 |
2015-05-27 |
Bergenbio As |
Humanized anti-axl antibodies
|
|
GB201506399D0
(en)
*
|
2015-04-15 |
2015-05-27 |
Berkel Patricius H C Van And Howard Philip W |
Site-specific antibody-drug conjugates
|
|
GB201506405D0
(en)
*
|
2015-04-15 |
2015-05-27 |
Berkel Patricius H C Van And Howard Philip W |
Site-specific antibody-drug conjugates
|
|
GB201506389D0
(en)
*
|
2015-04-15 |
2015-05-27 |
Berkel Patricius H C Van And Howard Philip W |
Site-specific antibody-drug conjugates
|
|
GB201506388D0
(en)
*
|
2015-04-15 |
2015-05-27 |
Berkel Patricius H C Van And Cancer Res Technology Ltd And Howard Philip W |
Site-specific antibody-drug conjugates
|
|
GB201506407D0
(en)
*
|
2015-04-15 |
2015-05-27 |
Berkel Patricius H C Van And Howard Philip W |
Site-specific antibody-drug conjugates
|
|
GB201506393D0
(en)
*
|
2015-04-15 |
2015-05-27 |
Berkel Patricius H C Van And Howard Philip W |
Site-specific antibody-drug conjugates
|
|
GB201506402D0
(en)
*
|
2015-04-15 |
2015-05-27 |
Berkel Patricius H C Van And Howard Philip W |
Site-specific antibody-drug conjugates
|
|
GB201506394D0
(en)
*
|
2015-04-15 |
2015-05-27 |
Berkel Patricius H C Van And Howard Philip W |
Site-specific antibody-drug conjugates
|
|
EP3297672B1
(en)
|
2015-05-21 |
2021-09-01 |
Harpoon Therapeutics, Inc. |
Trispecific binding proteins and methods of use
|
|
CA2990408A1
(en)
*
|
2015-06-23 |
2016-12-29 |
Bayer Pharma Aktiengesellschaft |
Antibody drug conjugates of kinesin spindel protein (ksp) inhibitors with anti-b7h3-antibodies
|
|
EP3337517A4
(en)
*
|
2015-08-20 |
2019-04-17 |
Abbvie Stemcentrx LLC |
ANTI-DLL3 ANTIBODY AGGREGATE CONJUGATES AND METHOD OF USE
|
|
GB201602363D0
(en)
*
|
2016-02-10 |
2016-03-23 |
Adc Therapeutics Sa And Medimmune Ltd |
Pyrrolobenzodiazepine conjugates
|
|
RU2756275C2
(ru)
|
2016-03-01 |
2021-09-29 |
Юссум Рисёрч Девелопмент Компани Оф Зэ Хибру Юниверсити Оф Иерусалим Лтд. |
Антитела, специфические к рецептору полиовируса (pvr) человека
|
|
KR102530742B1
(ko)
|
2016-05-20 |
2023-05-09 |
하푼 테라퓨틱스, 인크. |
단일 도메인 혈청 알부민 결합 단백질
|
|
KR20230047507A
(ko)
|
2016-06-27 |
2023-04-07 |
더 리젠츠 오브 더 유니버시티 오브 캘리포니아 |
암 치료 조합
|
|
GB201617466D0
(en)
|
2016-10-14 |
2016-11-30 |
Medimmune Ltd |
Pyrrolobenzodiazepine conjugates
|
|
RS61795B1
(sr)
|
2017-02-08 |
2021-06-30 |
Adc Therapeutics Sa |
Konjugati pirolobenzodiazepin antitela
|
|
GB201702031D0
(en)
|
2017-02-08 |
2017-03-22 |
Medlmmune Ltd |
Pyrrolobenzodiazepine-antibody conjugates
|
|
SMT202200490T1
(it)
|
2017-04-18 |
2023-01-13 |
Medimmune Ltd |
Coniugati di pirrolobenzodiazepina
|
|
WO2018193102A1
(en)
|
2017-04-20 |
2018-10-25 |
Adc Therapeutics Sa |
Combination therapy with an anti-axl antibody-drug conjugate
|
|
KR102442736B1
(ko)
|
2017-06-14 |
2022-09-16 |
에이디씨 테라퓨틱스 에스에이 |
항-cd19 adc의 투여를 위한 투약량 체제
|
|
CN108743968B
(zh)
*
|
2017-06-20 |
2022-04-19 |
成都百利多特生物药业有限责任公司 |
半胱氨酸改造的抗体-毒素偶联物(tdc)定点偶联位点筛选
|
|
SI3668874T1
(sl)
|
2017-08-18 |
2022-04-29 |
Medimmune Limited |
Pirolobenzodiazepinski konjugati
|
|
CA3177215C
(en)
|
2017-09-29 |
2026-06-09 |
Daiichi Sankyo Company, Limited |
Antibody-pyrrolobenzodiazepine derivative conjugate
|
|
IL315737A
(en)
|
2017-10-13 |
2024-11-01 |
Harpoon Therapeutics Inc |
B-cell maturation antigen-binding proteins
|
|
CA3078969A1
(en)
|
2017-10-13 |
2019-04-18 |
Harpoon Therapeutics, Inc. |
Trispecific proteins and methods of use
|
|
EP3700577A1
(en)
*
|
2017-10-23 |
2020-09-02 |
Mablink Bioscience |
Ligand-drug-conjugate comprising a single molecular weight polysarcosine
|
|
GB201803342D0
(en)
|
2018-03-01 |
2018-04-18 |
Medimmune Ltd |
Methods
|
|
GB201806022D0
(en)
|
2018-04-12 |
2018-05-30 |
Medimmune Ltd |
Pyrrolobenzodiazepines and conjugates thereof
|
|
AU2019267349B2
(en)
*
|
2018-05-08 |
2025-06-05 |
Phanes Therapeutics, Inc. |
Anti-DLL3 antibodies and uses thereof
|
|
MX2020012217A
(es)
|
2018-05-14 |
2021-03-02 |
Harpoon Therapeutics Inc |
Porción de unión para activación condicional de moléculas de inmunoglobulina.
|
|
US12018087B2
(en)
|
2018-08-02 |
2024-06-25 |
Dyne Therapeutics, Inc. |
Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject
|
|
EP3830259A4
(en)
|
2018-08-02 |
2022-05-04 |
Dyne Therapeutics, Inc. |
MUSCLE TARGETED COMPLEXES AND THEIR USES IN THE TREATMENT OF FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY
|
|
US12097263B2
(en)
|
2018-08-02 |
2024-09-24 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating myotonic dystrophy
|
|
US11911484B2
(en)
|
2018-08-02 |
2024-02-27 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating myotonic dystrophy
|
|
WO2020028832A1
(en)
|
2018-08-02 |
2020-02-06 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating dystrophinopathies
|
|
US11168141B2
(en)
|
2018-08-02 |
2021-11-09 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating dystrophinopathies
|
|
US12195544B2
(en)
|
2018-09-21 |
2025-01-14 |
Harpoon Therapeutics, Inc. |
EGFR binding proteins and methods of use
|
|
CN112839676B
(zh)
*
|
2018-10-10 |
2024-10-25 |
武田药品工业株式会社 |
制造抗体药物偶联物的方法
|
|
CA3119956A1
(en)
|
2018-11-14 |
2020-05-22 |
Daiichi Sankyo Company, Limited |
Anti-cdh6 antibody-pyrrolobenzodiazepine derivative conjugate
|
|
CN113631560B
(zh)
|
2019-03-15 |
2025-02-18 |
麦迪穆有限责任公司 |
氮杂环丁烷并苯并二氮杂䓬二聚体和用于治疗癌症的包含它们的缀合物
|
|
EP3950061A4
(en)
|
2019-03-25 |
2022-11-16 |
Daiichi Sankyo Company, Limited |
ANTIBODY PYRROLOBENZODIAZEPINE DERIVATIVE CONJUGATE
|
|
BR112021017616A2
(pt)
|
2019-03-25 |
2021-11-09 |
Daiichi Sankyo Co Ltd |
Conjugado de derivado de anticorpo anti-her2-pirrolobenzodiazepina
|
|
EP3949988A4
(en)
|
2019-03-27 |
2022-11-16 |
Daiichi Sankyo Company, Limited |
COMBINATION OF AN ANTIBODY-PYRROLOBENZODIAZEPINE DERIVATIVE CONJUGATE AND A PARP INHIBITOR
|
|
WO2020232303A1
(en)
|
2019-05-14 |
2020-11-19 |
Harpoon Therapeutics, Inc. |
EpCAM BINDING PROTEINS AND METHODS OF USE
|
|
MX2022000174A
(es)
|
2019-07-02 |
2022-05-20 |
Us Health |
Anticuerpos monoclonales que se enlazan a egfrviii y sus usos.
|
|
KR20220082007A
(ko)
|
2019-10-08 |
2022-06-16 |
넥틴 테라퓨틱스 리미티드 |
폴리오바이러스 수용체(pvr)에 대한 항체 및 이의 용도
|
|
IL295022A
(en)
*
|
2020-01-31 |
2022-09-01 |
Dyne Therapeutics Inc |
Antibody against transferrin receptor and uses thereof
|
|
WO2021154477A1
(en)
|
2020-01-31 |
2021-08-05 |
Dyne Therapeutics, Inc. |
Anti-transferrin receptor (tfr) antibody and uses thereof
|
|
US11969475B2
(en)
|
2021-07-09 |
2024-04-30 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
|
|
US11633498B2
(en)
|
2021-07-09 |
2023-04-25 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating myotonic dystrophy
|
|
US11672872B2
(en)
|
2021-07-09 |
2023-06-13 |
Dyne Therapeutics, Inc. |
Anti-transferrin receptor antibody and uses thereof
|
|
US11638761B2
(en)
|
2021-07-09 |
2023-05-02 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy
|
|
US11771776B2
(en)
|
2021-07-09 |
2023-10-03 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating dystrophinopathies
|
|
EP4209506A4
(en)
|
2020-09-02 |
2024-10-09 |
Daiichi Sankyo Company, Limited |
NEW ENDO-N-ACETYL GLUCOSAMINIDASE
|
|
CN117425501A
(zh)
|
2021-01-13 |
2024-01-19 |
纪念斯隆凯特琳癌症中心 |
抗体-吡咯并苯二氮䓬衍生物缀合物
|
|
WO2023283623A1
(en)
|
2021-07-09 |
2023-01-12 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and formulations for treating dystrophinopathies
|
|
JP7892050B2
(ja)
*
|
2021-07-30 |
2026-07-17 |
シャンハイ フダン－チャンジャン バイオ－ファーマシューティカル カンパニー リミテッド |
抗ｄｌｌ３抗体とその製造方法、その薬物複合体及び使用
|
|
AU2022345323A1
(en)
*
|
2021-09-17 |
2024-03-28 |
WuXi Biologics Ireland Limited |
D3-binding molecules and uses thereof
|
|
WO2023100829A1
(ja)
|
2021-11-30 |
2023-06-08 |
第一三共株式会社 |
プロテアーゼ分解性マスク抗体
|
|
TW202346346A
(zh)
*
|
2021-12-23 |
2023-12-01 |
大陸商江蘇恆瑞醫藥股份有限公司 |
抗ｄｌｌ３抗體、其抗體－藥物偶聯物及其醫藥用途
|
|
AU2023218678A1
(en)
|
2022-02-09 |
2024-08-01 |
Daiichi Sankyo Company, Limited |
Environmentally responsive masked antibody and use thereof
|
|
IL315341A
(en)
|
2022-03-02 |
2024-10-01 |
Daiichi Sankyo Co Ltd |
METHOD FOR PRODUCING Fc-CONTAINING MOLECULE
|
|
IL316143A
(en)
|
2022-04-15 |
2024-12-01 |
Dyne Therapeutics Inc |
Muscle targeting complexes and formulations for the treatment of myotonic dystrophy
|
|
EP4534101A1
(en)
|
2023-10-02 |
2025-04-09 |
Eli Lilly and Company |
Antibody drug conjugate (adc) targeting nectin 4 and comprising an exatecan payload
|
|
TW202600599A
(zh)
*
|
2024-03-11 |
2026-01-01 |
大陸商樂普生物科技股份有限公司 |
抗ｄｌｌ３抗體及其用途
|
|
CN119119255B
(zh)
*
|
2024-09-20 |
2026-03-03 |
广东省生物技术研究院(广东省实验动物监测中心) |
一种猪急性腹泻综合征冠状病毒的刺突蛋白抗原表位肽及其单克隆抗体与应用
|